16,621 reports of this reaction
2.2% of all RITUXIMAB reports
#5 most reported adverse reaction
FATIGUE is the #5 most commonly reported adverse reaction for RITUXIMAB, manufactured by Genentech, Inc.. There are 16,621 FDA adverse event reports linking RITUXIMAB to FATIGUE. This represents approximately 2.2% of all 743,156 adverse event reports for this drug.
RITUXIMAB has an overall safety score of 85 out of 100. Patients taking RITUXIMAB who experience fatigue should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
FATIGUE is a less commonly reported adverse event for RITUXIMAB, but still significant enough to appear in the safety profile.
In addition to fatigue, the following adverse reactions have been reported for RITUXIMAB:
The following drugs have also been linked to fatigue in FDA adverse event reports:
FATIGUE has been reported as an adverse event in 16,621 FDA reports for RITUXIMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
FATIGUE accounts for approximately 2.2% of all adverse event reports for RITUXIMAB, making it a notable side effect.
If you experience fatigue while taking RITUXIMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.